Brief: Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed
18/11/2025 13:09
Nasus Pharma Ltd NSRX.A: NASUS PHARMA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY OF NS002 WITH FIRST PARTICIPANT DOSED NASUS PHARMA LTD - INTERIM RESULTS EXPECTED IN Q1 2026 Source text: ID:nGNX1s15SJ Further company coverage: NSRX.A
Recent news on Nasus Pharma
See all newsBrief: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady As Chief Executive Officer To Lead Strategic Growth
Brief: Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
Brief: Nasus Pharma Announces Closing Of $15.0 Million Private Placement
Brief: Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer
Brief: Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed